Challenges Faced by Multidrug-Resistant Tuberculosis Patients in Three Financially Affluent Chinese Cities

References

• World Health Organization. Global tuberculosis report 2019. 2019.
   Google Scholar
• Haileamlak A. Infectious diseases continued to be the world’s core challenge. Ethiop J Health Sci. 2017;27(6):570. doi:10.4314/ejhs.v27i6.129487465
   PubMedGoogle Scholar
• Meng Q, Xu K. Progress and challenges of the rural cooperative medical scheme in China. Bull World Health Organ. 2014;92(6):447–451.24940019
   PubMed Web of Science ®Google Scholar
• Pan XF, Xu J, Meng Q. Integrating social health insurance systems in China. Lancet. 2016;387(10025):1274–1275. doi:10.1016/S0140-6736(16)30021-6
   Web of Science ®Google Scholar
• Meng Q, Fang H, Liu X, Yuan B, Xu J. Consolidating the social health insurance schemes in China: towards an equitable and efficient health system. Lancet. 2015;386(10002):1484–1492. doi:10.1016/S0140-6736(15)00342-626466052
   PubMed Web of Science ®Google Scholar
• Li C, Hou Y, Sun M, et al. An evaluation of China’s new rural cooperative medical system: achievements and inadequacies from policy goals. BMC Public Health. 2015;15:1079.26494015
   PubMed Web of Science ®Google Scholar
• Yuan B, Jian W, He L, Wang B, Balabanova D. The role of health system governance in strengthening the rural health insurance system in China. Int J Equity Health. 2017;16(1):44. doi:10.1186/s12939-017-0542-x28532418
   PubMed Web of Science ®Google Scholar
• Yi Wen. Income and living standards across China. January 8, 2018. Available from: https://www.stlouisfed.org/on-the-economy/2018/january/income-living-standards-china. Accessed October 28, 2020.
   Google Scholar
• Liu Y, Pang Y, Du J, et al. An overview of tuberculosis-designated hospitals in China, 2009–2015: a longitudinal analysis of national survey data. Biomed Res Int. 2019;2019:9310917.31531372
   PubMed Web of Science ®Google Scholar
• Tanimura T, Jaramillo E, Weil D, Raviglione M, Lonnroth K. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J. 2014;43(6):1763–1775.24525439
   PubMed Web of Science ®Google Scholar
• Wang Y The management of pulmonary multi-drug resistant tuberculosis. (in Chinese).
   Google Scholar
• Tang S. Tackling challenges of TB/MDRTB in China: concerted actions are imperative. Infect Dis Poverty. 2015;4:19.25908975
   PubMed Web of Science ®Google Scholar
• Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J. 2014;43(2):554–565. doi:10.1183/09031936.0007941323949960
   PubMed Web of Science ®Google Scholar
• Long Q, Smith H, Zhang T, Tang S, Garner P. Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review. BMC Public Health. 2011;11:393. doi:10.1186/1471-2458-11-39321615930
   PubMed Web of Science ®Google Scholar
• Hutchison C, Khan MS, Yoong J, Lin X, Coker RJ. Financial barriers and coping strategies: a qualitative study of accessing multidrug-resistant tuberculosis and tuberculosis care in Yunnan, China. BMC Public Health. 2017;17(1):221.28222724
   PubMed Web of Science ®Google Scholar
• Long Q, Qu Y, Lucas H. Drug-resistant tuberculosis control in China: progress and challenges. Infect Dis Poverty. 2016;5:9.26822738
   PubMed Web of Science ®Google Scholar
• Zhou C, Long Q, Chen J, et al. Factors that determine catastrophic expenditure for tuberculosis care: a patient survey in China. Infect Dis Poverty. 2016;5:6. doi:10.1186/s40249-016-0100-626806552
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang H, Pan Y, et al. Are free anti-tuberculosis drugs enough? An empirical study from three cities in China. Infect Dis Poverty. 2015;4:47. doi:10.1186/s40249-015-0080-y26510711
   PubMed Web of Science ®Google Scholar
• China GDP per capital, 1960–2019 data. Trading Economic. Available from: https://tradingeconomics.com/china/gdp-per-capita. Accessed October 28, 2020.
   Google Scholar
• Anti-tuberculosis association of China. Guideline of Chemotherapy for multi-drug resistance tuberculosis (2015) (in Chinese). Zhongguo Fang Lao Za Zhi. 2015;37(5):421–469.
   Google Scholar
• World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis (2016 update). 2016.
   Google Scholar
• Wu S, Zhang Y, Sun F, et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am J Ther. 2016;23(2):e521–530. doi:10.1097/01.mjt.0000433951.09030.5a24284652
   PubMed Web of Science ®Google Scholar
• Javaid A, Ullah I, Masud H, et al. Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study. Clin Microbiol Infect. 2018;24(6):612–617. doi:10.1016/j.cmi.2017.09.01228970158
   PubMed Web of Science ®Google Scholar
• Morris MD, Quezada L, Bhat P, et al. Social, economic, and psychological impacts of MDR-TB treatment in Tijuana, Mexico: a patient’s perspective. Int J Tuberc Lung Dis. 2013;17(7):954–960. doi:10.5588/ijtld.12.048023743315
   PubMed Web of Science ®Google Scholar
• Xu M, Markstrom U, Lyu J, Xu L. Survey on tuberculosis patients in rural areas in china: tracing the role of stigma in psychological distress. Int J Environ Res Public Health. 2017;14(10):1171. doi:10.3390/ijerph14101171
   Web of Science ®Google Scholar
• Bastos ML, Lan Z, Menzies D. An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. Eur Respir J. 2017;49(3).
   PubMed Web of Science ®Google Scholar
• Collaborative Group for the Meta-Analysis of Individual Patient Data in MDRTBt; Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821–834. doi:10.1016/S0140-6736(18)31644-1.30215381
   PubMed Web of Science ®Google Scholar
• Xu C, Pang Y, Li R, et al. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. J Infect. 2018;76(4):348–353. doi:10.1016/j.jinf.2017.12.01729374587
   PubMed Web of Science ®Google Scholar
• Yang C, Shen X, Peng Y, et al. Transmission of Mycobacterium tuberculosis in China: a population-based molecular epidemiologic study. Clin Infect Dis. 2015;61(2):219–227.25829000
   PubMed Web of Science ®Google Scholar
• Yang C, Luo T, Shen X, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis. 2017;17(3):275–284. doi:10.1016/S1473-3099(16)30418-227919643
   PubMed Web of Science ®Google Scholar